NTRK fusion cancer: what the result means for targeted treatment

Understand the finding in plain language

An NTRK fusion joins part of an NTRK gene to another gene and can create a growth signal that drives a tumor. This is different from a report describing protein expression or an unrelated change in the gene. Ask the clinician to point to the exact fusion result.

Because the same driver can occur in different organs, some drugs are used according to the molecular finding rather than the organ alone. This is called tumor-agnostic treatment. The original cancer diagnosis still matters for staging, local treatment and the alternatives available.

Sources and references: [1]

Check how the fusion was established

Testing methods can include sequencing and other laboratory approaches. The clinician and pathologist should consider whether the method used can detect the relevant fusion reliably and whether an initial screening result needs confirmation.

Send the complete report, including the sample, testing method and gene partner if listed. If a previous test was negative, ask what it actually covered before repeating it. The useful question is whether a different method or sample would resolve a treatment decision that remains uncertain.

Sources and references: [1]

Put TRK inhibitors beside the other treatment choices

TRK inhibitors are targeted drugs used in selected NTRK fusion-positive cancers. Larotrectinib, entrectinib and repotrectinib have different indications and supporting evidence. A specialist should compare them in the context of your age, cancer extent, previous medicines and other medical conditions.

If surgery or another local treatment could be effective, ask how that option fits with systemic therapy. For a tumor whose removal would cause major loss of function, the molecular finding may make a targeted-treatment discussion especially relevant. The sequence should be agreed by the relevant disease specialists.

Sources and references: [1] [2]

Who the US repotrectinib indication covers

Repotrectinib received US accelerated approval for adults and children aged 12 years or older with NTRK fusion-positive solid tumors that are locally advanced or metastatic, or for which surgery would likely cause severe morbidity. The indication also requires progression after treatment or no satisfactory alternative therapy.

The TRIDENT-1 study included adults who had and had not previously received a TRK inhibitor. If repotrectinib is being considered, ask how your prior treatment and molecular findings compare with that evidence. For care in China, the receiving team should check the current local indication and prescribing pathway.

Sources and references: [2]

When a previous TRK inhibitor stops working

Progression during targeted treatment calls for a review of the pattern of growth and possible resistance mechanisms. A new biopsy or blood-based test may be considered if it could guide the next choice. The team also assesses whether only a limited area has progressed or the disease has changed more widely.

Ask whether the next drug is intended to address a known resistance finding and what evidence supports that choice. Keep the earlier fusion report, all targeted-treatment dates and scans showing response and progression. That record makes a later-line consultation much more informative.

Sources and references: [1] [2]

Prepare for effects that can change daily activities

Repotrectinib can cause dizziness, altered taste, nerve symptoms, fatigue, balance problems and cognitive effects, among other adverse reactions. Discuss driving, falls and activities that require steady coordination before starting. Report changes early so the team can review treatment and support.

Ask for the medicine-specific laboratory and clinical monitoring schedule and a check of possible drug interactions. Include supplements and medicines obtained without a prescription. An oral treatment also needs a reliable plan for follow-up, repeat prescriptions and advice if a dose is missed or side effects develop.

Sources and references: [2]

Make the recommendation easy to act on

Request a written summary stating the confirmed fusion, the proposed drug, the treatment setting and the main alternative. It should explain when response will be assessed and which result would lead to continuation, adjustment or a change in treatment.

If the proposal is a clinical trial, ask for the identifier and screening conditions. Clarify which tests need to be repeated and whether they can be done near home. This prevents the family from arranging travel before learning that a key molecular or treatment-history requirement still needs review.

Sources and references: [3] [1]

Organize a molecular and disease-specific review

Fudan University Shanghai Cancer Center has pathology and multiple disease-specific oncology services. An NTRK fusion review should connect the molecular finding with the specialist who treats the original cancer and the clinician considering the targeted medicine.

Send EastMedGo the full molecular and pathology reports, imaging and prior treatment list. State whether a TRK inhibitor has already been used and why it stopped. We can organize a focused consultation request and help clarify the testing, prescribing and practical arrangements needed before you make travel plans.

Sources and references: [4]

Common questions